Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 03:43PM EDT. Market open.
Currency in USD
Valuation Measures4
| Market Cap (intraday) | 3.40B |
| Enterprise Value | 3.03B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.12 |
| Price/Book (mrq) | 24.24 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Stock Price History
| Beta (5Y Monthly) | 0.68 |
| 52-Week Change 3 | -16.56% |
| S&P500 52-Week Change 3 | 26.27% |
| 52 Week High 3 | 54.98 |
| 52 Week Low 3 | 31.52 |
| 50-Day Moving Average 3 | 46.32 |
| 200-Day Moving Average 3 | 42.09 |
Share Statistics
| Avg Vol (3 month) 3 | 738.26k |
| Avg Vol (10 day) 3 | 856.34k |
| Shares Outstanding 5 | 83.13M |
| Implied Shares Outstanding 6 | 83.13M |
| Float 8 | 73.41M |
| % Held by Insiders 1 | 4.02% |
| % Held by Institutions 1 | 101.09% |
| Shares Short (Apr 30, 2024) 4 | 4.65M |
| Short Ratio (Apr 30, 2024) 4 | 6.44 |
| Short % of Float (Apr 30, 2024) 4 | 6.52% |
| Short % of Shares Outstanding (Apr 30, 2024) 4 | 5.59% |
| Shares Short (prior month Mar 28, 2024) 4 | 3.92M |
Dividends & Splits
| Forward Annual Dividend Rate 4 | N/A |
| Forward Annual Dividend Yield 4 | N/A |
| Trailing Annual Dividend Rate 3 | 0.00 |
| Trailing Annual Dividend Yield 3 | 0.00% |
| 5 Year Average Dividend Yield 4 | N/A |
| Payout Ratio 4 | 0.00% |
| Dividend Date 3 | N/A |
| Ex-Dividend Date 4 | N/A |
| Last Split Factor 2 | N/A |
| Last Split Date 3 | N/A |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | Dec 31, 2023 |
| Most Recent Quarter (mrq) | Mar 31, 2024 |
Profitability
| Profit Margin | -138.58% |
| Operating Margin (ttm) | -151.93% |
Management Effectiveness
| Return on Assets (ttm) | -26.97% |
| Return on Equity (ttm) | -340.05% |
Income Statement
| Revenue (ttm) | 442.59M |
| Revenue Per Share (ttm) | 5.75 |
| Quarterly Revenue Growth (yoy) | 8.30% |
| Gross Profit (ttm) | N/A |
| EBITDA | -550.84M |
| Net Income Avi to Common (ttm) | -613.35M |
| Diluted EPS (ttm) | -7.95 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 412.08M |
| Total Cash Per Share (mrq) | 4.96 |
| Total Debt (mrq) | 932.17M |
| Total Debt/Equity (mrq) | 664.59% |
| Current Ratio (mrq) | 2.43 |
| Book Value Per Share (mrq) | 1.69 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -508.67M |
| Levered Free Cash Flow (ttm) | -329.48M |
© 2024 Yahoo. All rights reserved.